Comparison of Intravitreal Bevacizumab Injection with Combination of Suprachoroidal Triamcinolone Acetonide Along with Intravitreal Bevacizumab Injection in the Treatment of Diabetic Macular Edema in Pseudophakic Patients

Sponsor
Khyber Teaching Hospital
Study ID
NCT06882551
Phase
PHASE4
Status
Completed

Conditions

  • Diabetic Macular Edema (DME)

Eligibility Criteria

Sex
ALL
Age
32 Years - 78 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Patients were included in the study who were pseudophakic with center-involved (sub-foveal) diabetic macular edema

Key Dates

First listed
Mar 18, 2025
Start date
Apr 1, 2023
Status verified
Mar 2025
Primary completion
Nov 30, 2023
Completion
Jan 15, 2024

Study Design

Enrollment
82 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Intravitreal Bevacizumab alone for center involving diabetic macular edema
    Effect of intravitreal Bevacizumab 1.25mg on center involving diabetic macular edema
  • Experimental: Suprachoroidal triamcinolone acetonide and intravitreal Bevacizumab
    Combination of suprachoroidal triamcinolone acetonide and intravitreal Bevacizumab for the treatment of diabetic macular edema

Primary Outcome Measure

Central macular thickness [ Time Frame: 3 months ]

Related Studies